The ASRM published their 2026 guidelines on managing recurrent pregnancy loss (RPL), reviewing which tests and treatments are supported by evidence, which may be considered in certain situations, and which are not routinely recommended.
Endometrial receptivity array (ERA)
A 2026 meta-analysis found no benefit of ERA or other endometrial receptivity tests in general IVF patients, with a possible improvement in live birth for RIF patients transferring untested embryos.
The Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) has issued new guidelines on 28 IVF add-ons, outlining which may help in certain situations, which lack evidence, and which should be limited to research.
Researchers in a 2023 study review the use of 27 IVF add-ons and provide recommendations by ESHRE, with only several that are recommended or could be considered for the general infertility population.
Researchers in a 2023 study combined the results of 74 studies to investigate what factors contribute to euploid live birth and miscarriage rates, identifying embryo quality, maternal age, specific diagnoses, repeat freeze/thaw, and other factors.
Researchers in a 2022 study found no difference in live birth rates in those that transferred embryos by standard timing or timing established by the ERA.
Researchers in a 2022 study performed a meta-analysis to combine the results of 8 ERA studies and found no differences in live birth, pregnancy and miscarriage rates among women who performed the ERA or didn’t.
Researchers in a 2022 study found no benefit in patients who used the ERA after transferring a single euploid, even when accounting for a history of failed transfers.
